Intravenous Immunoglobulin Market to Reach $20.24 Billion by 2028 at 8.1% CAGR, Driven by Autoimmune Disorder Incidence

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Intravenous Immunoglobulin Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $3.66 billion In 2028 At A CAGR Of 11.5%:

The intravenous immunoglobulin market size has grown strongly in recent years. It will grow from $13.82 billion in 2023 to $14.84 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to treatment of primary immunodeficiency disorders, management of neurological disorders, rising geriatric population, advancements in plasma fractionation techniques, expanded indications in neurology, treatment of infectious diseases, pediatric immunodeficiency treatment.

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $20.24 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing incidence of autoimmune disorders, ongoing research in immunology, rising healthcare expenditure, growth in cancer incidence, innovation in immunoglobulin products, personalized medicine approaches. Major trends in the forecast period include primary immunodeficiency disorders (pidd) treatment, rapid technological innovations, strategic collaborations and partnerships, advancements in manufacturing processes, indications in neurology, use in hematology, advances in immunotherapy.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Intravenous Immunoglobulin Market Major Segments
The intravenous immunoglobulin market covered in this report is segmented -
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care

Key Driver - Rising Geriatric Population Fuels Growth In The Intravenous Immunoglobulin Market

The increasing geriatric population is expected to drive the intravenous immunoglobulin market forward. The geriatric population refers to the population above 65 years of age. As people grow old, their immunity does not work properly and there is a lack of antibodies. Therefore, they need immunoglobulins to provide them with antibodies. This increases demand for intravenous immunoglobulins and drives the intravenous immunoglobulin market forward. For instance, in 2021, according to the Elderly in India 2021 report by the National Statistical Office (NSO), a statistics wing of the Ministry of Statistics and Programme Implementation of the government of India, in 2021, 138 million elderly people were there in India and the number is expected to rise to 194 million by 2031. Additionally, according to the World Health Organization (WHO), a specialized agency of the United Nations, by 2030, 1 in 6 people in the world will be 60 years or older and the total number of people over 60 years will increase to 1.4 billion by 2030 increasing from 1 billion in 2020. As a result, the increasing geriatric population will drive the growth of the intravenous immunoglobulin market forward.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=8538&type=smp

Prominent Trend - Innovative Human Plasma-Derived Ivig Products Drive Advancements In The Intravenous Immunoglobulin Market

Product innovation is a key trend gaining popularity in the intravenous immunoglobulin market. Major companies in the market are focusing on innovating new products such as human plasma-derived intravenous immunoglobulin (IVIg) for the treatment of rare diseases and sustaining their position in the market. For instance, in June 2021, Octapharma, a Swiss pharmaceutical company, announced that its new product 'Octagam 10%', a human plasma-derived intravenous immunoglobulin (IVIg) was granted approval by the European Union (EU) as immunotherapy for adults with dermatomyositis, and national approval by Germany for the same indication. Octagam 10% is the first therapy to be approved for dermatomyositis in the EU and indicated for adults with active dermatomyositis treated with immunosuppressive drugs. This innovative product will help improve the lives of people with dermatomyositis, which is a rare, idiopathic autoimmune disorder.

Intravenous Immunoglobulin Market Players
Major companies operating in the intravenous immunoglobulin market report are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., Emergent BioSolutions Inc., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the intravenous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Intravenous Immunoglobulin Market Report Structure
3. Intravenous Immunoglobulin Market Trends And Strategies
4. Intravenous Immunoglobulin Market - Macro Economic Scenario
5. Intravenous Immunoglobulin Market Size And Growth
…..
27. Intravenous Immunoglobulin Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.